Because odevixibat does not target specific genes or mutations, the efficacy of odevixibat for pruritus was extrapolated to all PFIC subtypes except for PFIC2/BSEP-3 and the labeling indication was approved for all PFIC subtypes. Here, ABCB11 is linked to progressive familial intrahepatic cholestasis.